CRI vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CRI exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a robust current ratio of 2.51, indicating low immediate insolvency risk. While the stock is attractively valued relative to the sector (P/E 14.70 vs 35.14) and trades near its Graham Number of $38.02, it is hampered by a long-term bearish price trend (-55.4% over 5 years) and sluggish earnings growth. The disconnect between strong balance sheet health and poor price performance suggests a value trap scenario unless growth accelerates. Overall, the company is a stable 'Hold' with limited immediate catalysts for a breakout.
Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.
Compare Another Pair
Related Comparisons
CRI vs TSLA: Head-to-Head Comparison
This page compares Carter's, Inc. (CRI) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.